Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease in the United States (GERAS-US)

– Presents within normal course of outpatient care for whom the physician deems to meet
clinical criteria for MCI due to AD or mild AD dementia.

– Fully informed written consent of the participant (or his/her legal representative).

– Study partner who has frequent contact with the participant is willing to accompany
the participant at the study observations.

– Fully informed written consent of the study partner; this person must be willing to
serve as study partner for at least 6 months of the year.

– Able to communicate in English and/or US Spanish.

– Able to provide evidence of amyloid testing.

– Has an Mini-Mental State Examination (MMSE) score of 20 or greater.

Exclusion Criteria:

– Are currently enrolled in any other clinical trial involving an investigational
product or any other type of medical research judged not to be scientifically or
medically compatible with this study at baseline.

– Are investigator site personnel directly affiliated with this study and/or their
immediate families. Immediate family is defined as a spouse, parent, child, or
sibling, whether biological or legally adopted.

– Lack of evidence of amyloid positivity through pre-study test. Note: After baseline
assessment, participants with amyloid negativity identified as part of the study will
not continue in post-baseline assessments.

– Are Lilly employees or are employees of any third-party organization (TPO) involved in
study who require exclusion of their employees.